Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.
Identifieur interne : 001267 ( PubMed/Curation ); précédent : 001266; suivant : 001268Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.
Auteurs : Kyle G. Melvin [Canada] ; Jon Doan ; Sergio M. Pellis ; Lesley Brown ; Ian Q. Whishaw ; Oksana SuchowerskySource :
- Behavioural brain research [ 0166-4328 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Case-Control Studies, Deep Brain Stimulation (methods), Follow-Up Studies, Functional Laterality, Globus Pallidus (drug effects), Globus Pallidus (physiopathology), Globus Pallidus (radiation effects), Humans, Levodopa (therapeutic use), Middle Aged, Parkinson Disease (physiopathology), Parkinson Disease (therapy), Prospective Studies, Psychomotor Performance (drug effects), Psychomotor Performance (physiology), Psychomotor Performance (radiation effects), Statistics, Nonparametric, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Globus Pallidus, Psychomotor Performance.
- methods : Deep Brain Stimulation.
- physiology : Psychomotor Performance.
- physiopathology : Globus Pallidus, Parkinson Disease.
- radiation effects : Globus Pallidus, Psychomotor Performance.
- therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Follow-Up Studies, Functional Laterality, Humans, Middle Aged, Prospective Studies, Statistics, Nonparametric, Treatment Outcome.
Abstract
To determine effects of dopaminergic medication and pallidal deep brain stimulation (DBS) on skilled reach in Parkinson's disease (PD).
DOI: 10.1016/j.bbr.2004.12.001
PubMed: 15836914
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001267
Links to Exploration step
pubmed:15836914Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.</title><author><name sortKey="Melvin, Kyle G" sort="Melvin, Kyle G" uniqKey="Melvin K" first="Kyle G" last="Melvin">Kyle G. Melvin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, Faculty of Medicine, Movement Disorders Program, Foothills Hospital, University of Calgary, Area 33350, Hospital Dr NW, Calgary, Alta., Canada T2N 4N1. kgmelvin@ucalgary.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Clinical Neurosciences, Faculty of Medicine, Movement Disorders Program, Foothills Hospital, University of Calgary, Area 33350, Hospital Dr NW, Calgary, Alta.</wicri:regionArea></affiliation></author><author><name sortKey="Doan, Jon" sort="Doan, Jon" uniqKey="Doan J" first="Jon" last="Doan">Jon Doan</name></author><author><name sortKey="Pellis, Sergio M" sort="Pellis, Sergio M" uniqKey="Pellis S" first="Sergio M" last="Pellis">Sergio M. Pellis</name></author><author><name sortKey="Brown, Lesley" sort="Brown, Lesley" uniqKey="Brown L" first="Lesley" last="Brown">Lesley Brown</name></author><author><name sortKey="Whishaw, Ian Q" sort="Whishaw, Ian Q" uniqKey="Whishaw I" first="Ian Q" last="Whishaw">Ian Q. Whishaw</name></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15836914</idno><idno type="pmid">15836914</idno><idno type="doi">10.1016/j.bbr.2004.12.001</idno><idno type="wicri:Area/PubMed/Corpus">001267</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001267</idno><idno type="wicri:Area/PubMed/Curation">001267</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001267</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.</title><author><name sortKey="Melvin, Kyle G" sort="Melvin, Kyle G" uniqKey="Melvin K" first="Kyle G" last="Melvin">Kyle G. Melvin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, Faculty of Medicine, Movement Disorders Program, Foothills Hospital, University of Calgary, Area 33350, Hospital Dr NW, Calgary, Alta., Canada T2N 4N1. kgmelvin@ucalgary.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Clinical Neurosciences, Faculty of Medicine, Movement Disorders Program, Foothills Hospital, University of Calgary, Area 33350, Hospital Dr NW, Calgary, Alta.</wicri:regionArea></affiliation></author><author><name sortKey="Doan, Jon" sort="Doan, Jon" uniqKey="Doan J" first="Jon" last="Doan">Jon Doan</name></author><author><name sortKey="Pellis, Sergio M" sort="Pellis, Sergio M" uniqKey="Pellis S" first="Sergio M" last="Pellis">Sergio M. Pellis</name></author><author><name sortKey="Brown, Lesley" sort="Brown, Lesley" uniqKey="Brown L" first="Lesley" last="Brown">Lesley Brown</name></author><author><name sortKey="Whishaw, Ian Q" sort="Whishaw, Ian Q" uniqKey="Whishaw I" first="Ian Q" last="Whishaw">Ian Q. Whishaw</name></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author></analytic><series><title level="j">Behavioural brain research</title><idno type="ISSN">0166-4328</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Deep Brain Stimulation (methods)</term><term>Follow-Up Studies</term><term>Functional Laterality</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (physiopathology)</term><term>Globus Pallidus (radiation effects)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Prospective Studies</term><term>Psychomotor Performance (drug effects)</term><term>Psychomotor Performance (physiology)</term><term>Psychomotor Performance (radiation effects)</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Globus Pallidus</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Globus Pallidus</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Globus Pallidus</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Follow-Up Studies</term><term>Functional Laterality</term><term>Humans</term><term>Middle Aged</term><term>Prospective Studies</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine effects of dopaminergic medication and pallidal deep brain stimulation (DBS) on skilled reach in Parkinson's disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15836914</PMID><DateCreated><Year>2005</Year><Month>04</Month><Day>19</Day></DateCreated><DateCompleted><Year>2005</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-4328</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation></Journal><ArticleTitle>Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>188-94</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine effects of dopaminergic medication and pallidal deep brain stimulation (DBS) on skilled reach in Parkinson's disease (PD).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">PD is a neurodegenerative disorder affecting motor control. While speed and execution of movements are improved by L-dopa, not all motor symptoms are alleviated. Little is known about the effects of DBS or medication on reaching.</AbstractText><AbstractText Label="DESIGN METHOD" NlmCategory="UNASSIGNED">Eight PD patients with unilateral pallidal DBS reached with the contra-lateral hand for a piece of food, placing it in the mouth, and returning to starting position. Testing was performed on no treatment, medication only, DBS only, and combined treatment. Reaches were digitally recorded and analyzed on a 21 point scale adapted from Eshkol-Wachman Notation. Analysis was blinded, with patients compared to age-matched controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were tested 6-13 months after surgery. All showed significant improvement clinically and in UPDRS (III) scores. The following data were obtained on the reaching scale: normal controls 16.5-21.0 (mean 18.3), no treatment 3.0-12.5 (mean 7.4), medication only 7.0-14.0 (mean 10.3), DBS only 4.5-16.0 (mean 9.2), combined treatment 4.0-15.0 (mean 9.5). The difference between controls and all treatment groups was statistically significant (P<0.005). All aspects of reach were compromised. No significant differences were found among the four conditions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study is consistent with accumulating evidence that some aspects of motor performance in PD patients, such as reaching, are resistant to L-dopa. Also, pallidal DBS does not improve those parameters that are resistant to L-dopa, either alone or in combination with medication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Melvin</LastName><ForeName>Kyle G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Faculty of Medicine, Movement Disorders Program, Foothills Hospital, University of Calgary, Area 33350, Hospital Dr NW, Calgary, Alta., Canada T2N 4N1. kgmelvin@ucalgary.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doan</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pellis</LastName><ForeName>Sergio M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Whishaw</LastName><ForeName>Ian Q</ForeName><Initials>IQ</Initials></Author><Author ValidYN="Y"><LastName>Suchowersky</LastName><ForeName>Oksana</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005917" MajorTopicYN="Y">Globus Pallidus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="Y">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>12</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15836914</ArticleId><ArticleId IdType="pii">S0166-4328(04)00455-3</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2004.12.001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001267 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001267 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15836914
|texte= Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15836914" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |